cyclo[(diaminoethylcarbamoyl)HyPro-Phe-D-Trp-Lys-Tyr(Bzl)-Phe]

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cyclo[(diaminoethylcarbamoyl)HyPro-Phe-D-Trp-Lys-Tyr(Bzl)-Phe]
• 英文别名: [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3,15-dibenzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
• 化学式: C₅₉H₆₈N₁₀O₉
• 分子量: 1061.25
• InChiKey: YNCDBNIRPHKYAI-CSRBYPKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  78
• 可旋转键数：
  19
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  281
• 氢给体数：
  9
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  Fmoc-L-苯丙氨酸 、 N-alpha-芴甲氧羰基-N-epsilon-叔丁氧羰基-L-赖氨酸 、 N-alpha-芴甲氧羰基-N-in-叔丁氧羰基-D-色氨酸 、 (2S,4R)-4-[[[[2-[[叔丁氧羰基]氨基]乙基]氨基]羰基]氧基]-1,2-吡咯烷二甲酸 1-(9H-芴-9-基甲基)酯 、 alkaline earth salt of/the/ methylsulfuric acid 生成 cyclo[(diaminoethylcarbamoyl)HyPro-Phe-D-Trp-Lys-Tyr(Bzl)-Phe]
  参考文献：
  名称：

  A Novel Somatostatin Mimic with Broad Somatotropin Release Inhibitory Factor Receptor Binding and Superior Therapeutic Potential

  摘要：

  A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials.

  DOI：

  10.1021/jm021093t

文献信息

• A Novel Somatostatin Mimic with Broad Somatotropin Release Inhibitory Factor Receptor Binding and Superior Therapeutic Potential
  作者：Ian Lewis、Wilfried Bauer、Rainer Albert、Nagarajan Chandramouli、Janos Pless、Gisbert Weckbecker、Christian Bruns

  DOI：10.1021/jm021093t

  日期：2003.6.1

  A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials.